Cover Image
市場調查報告書

全球核醫學/放射性醫藥品市場 - 機會及預測

World Nuclear Medicine/Radiopharmaceuticals Market - Opportunities and Forecasts, 2014 - 2022

出版商 Allied Market Research 商品編碼 367298
出版日期 內容資訊 英文 130 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球核醫學/放射性醫藥品市場 - 機會及預測 World Nuclear Medicine/Radiopharmaceuticals Market - Opportunities and Forecasts, 2014 - 2022
出版日期: 2016年07月01日 內容資訊: 英文 130 Pages
簡介

全球放射性醫藥品市場,預計至2022年達82億750萬美元。癌症病例數的增加和對核醫學的認識提高,拉抬市場成長。還有微創技術治療的便利性,與化療相比放射性醫藥品的治療成為患者偏好的理由。

本報告提供全球核醫學/放射性醫藥品市場相關調查,市場現狀及至2022年的預測,各類型,各種模式,各用途,各終端用戶,及各地區趨勢,參與企業簡介等彙整資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 調查結果
  • 波特五力分析
  • 臨床實驗
  • 政府的法規
  • 專利調查
  • 市場佔有率分析
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會

第4章 各類型市場

  • 概要
  • 診斷
  • 治療藥
  • 生物化學研究

第5章 各種模式市場

  • 概要
  • SPECT
  • PET
  • β發送器
  • Alpha發送器
  • 近距離放射治療

第6章 各用途市場

  • 概要
  • 腫瘤
  • 心臟
  • 甲狀腺
  • 神經
  • 其他

第7章 各終端用戶市場

  • 概要
  • 醫院及診斷中心
  • 研究機關

第8章 各地區市場

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美

第9章 企業簡介

  • Mallinckrodt plc.
  • General Electric Co.
  • Medtronic, plc.
  • Bayer AG
  • Cardinal Health, Inc.
  • Lantheus Medical Imaging, Inc.
  • IBA Group
  • Bracco Imaging S.p.A
  • NTP Radioisotopes SOC Ltd.
  • Advanced Accelerator Applications S.A

圖表

目錄

Title: World Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic, Therapeutic), Modality (SPECT, PET, Alpha-emitters, Beta-emitters, Brachytherapy), Application (Oncology, Cardiology, Neurology, Thyroid), Procedures (Central Nervous System, Endocrine, Skeletal, Gastrointestinal, Genito-urinary, Pulmonary) and End User (Hospitals and diagnostic centers, Research institutes) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022.

Radiopharmaceuticals are pharmaceutical formulations comprising radioactive isotopes that are used in diagnosis and therapeutics. They are simple and small substances that contain a radioactive substance that is used in the treatment of cancer and cardiac & neurological disorders. The conventional chemotherapy methods are being replaced by more convenient therapeutic radiopharmaceuticals for oncology and cancer treatment, which opens up new avenues in the radiopharmaceuticals market. Moreover, it not only helps physicians during diagnosis, but also works as a convenient and safer alternative for patients as compared to X-Rays and other external radiation imaging devices. Radiopharmaceuticals, also known as nuclear medicines, are used in applications such as lymphoma and bone metastasis. F-18, Tc-99, Ga-67, and I-123 are some of the nuclear medicines used in diagnostic procedures, while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are used in therapeutics procedures.

The world radiopharmaceuticals market is expected to generate a revenue of $8,207.5 million by 2022, the market is currently in its growth stage driven by increasing number of cancer cases and rising awareness about nuclear medicine. Convenience of the treatment with minimally invasive techniques attracts more patients towards radiopharmaceuticals mode of treatment as compared to chemotherapy. The factors that drive the Radiopharmaceuticals Industry include increasing incidence of cardiac patients and adoption of clear imaging technique, with the help of diagnostic equipment such as PET and SPECT. The factors that restrain the growth of the market include supply shortages, logistical difficulties, and limited number of trained medical personnel.

The report segments the radiopharmaceuticals industry on the basis of type, modality, application, end user, and geography. On the basis of type, the market is segmented into diagnostic, therapeutic, and research. Based on modality, the nuclear medicine market is segregated into SPECT, PET, alpha emitters, beta emitters, and brachytherapy. According to application, the market is classified into oncology, cardiology, neurology, thyroid, and others. The geographic breakdown and deep analysis of each of the aforesaid segments is included for North America, Europe, Asia-Pacific, and LAMEA. Asia-Pacific is the highest revenue generating region accounting for about 35.1% of the total market and is projected to grow at a high CAGR of 8.4% during the forecast period.

Comprehensive competitive analysis and profiles of major market players such as Mallinckrodt plc., General Electric Co. (healthcare division), Medtronic, Inc., Bayer AG, Cardinal Health, Inc., Lantheus Medical Imaging, Inc., and IBA Group is also provided in this report.

KEY BENEFITS FOR STAKEHOLDERS:

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the world nuclear medicine market.
  • This report includes a detailed quantitative analysis of the current market and estimations from 2014 to 2022, which contribute in identifying the key market opportunities for growth.
  • Exhaustive analysis of the world radiopharmaceuticals market by type helps in understanding the types of radiopharmaceuticals that are currently being used along with the variants that would gain prominence in the future.
  • Competitive intelligence (of leading manufacturers of radiopharmaceuticals) helps in understanding the competitive scenario across the geographies.
  • Key market players within the radiopharmaceuticals market are profiled in this report and their strategies are analyzed thoroughly. This helps in understanding the competitive outlook of the global nuclear medicine market.

NEUCLEAR MEDICINE/ RADIOPAHRMACEUTICALS MARKET KEY SEGMENTS:

By Type

  • Diagnostic
  • Therapeutic

By Modality

  • SPECT
  • PET
  • Alpha-emitters
  • Beta-emitters
  • Brachytherapy

By Application

  • Oncology
  • Cardiology
  • Neurology
  • Thyroid
  • Others

By Procedures

  • Oncology
  • Cardiovascular
  • Central Nervous System
  • Endocrine
  • Skeletal
  • Gastrointestinal
  • Genito-urinary
  • Pulmonary
  • PET & PET-CT
  • Therapeutic
  • Others

By End-user

  • Hospitals and diagnostic centers
  • Research institutes

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Belarus
    • Czech Republic
    • Greece
    • Hungary
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Korea
    • Pakistan
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Argentina
    • South Africa
    • Rest of LAMEA

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits
  • 1.3. Key market segments
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
  • 3.3. Porters five forces analysis
  • 3.4. Clinical trials
  • 3.5. Government regulations
  • 3.6. Patent study
  • 3.7. Market share analysis (2015)
  • 3.8. Market dynamics
    • 3.8.1. Drivers
      • 3.8.1.1. Increase in the number of new cancer cases
      • 3.8.1.2. Rising adoption of SPECT and PET Scans
      • 3.8.1.3. Increase in preference for radiotaion therapy for cancer treatment
      • 3.8.1.4. Developments in imaging technologies using radiopharmaceuticals
    • 3.8.2. Restraints
      • 3.8.2.1. Supply volatility, logistical challenges and stringent regulatory Policies
      • 3.8.2.2. Competition from conventional alternative diagnostic procedures
    • 3.8.3. Opportunities
      • 3.8.3.1. Multilateral supply agreements between countries
      • 3.8.3.2. Advances in neurological applications

CHAPTER 4: WORLD RADIOPHARMACEUTICALS MARKET, BY TYPE, 2014-2022

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Diagnostics
    • 4.2.1. Key market trends
    • 4.2.2. Key growth factors and opportunities
    • 4.2.3. Market size and forecast
  • 4.3. Therapeutics
    • 4.3.1. Key market trends
    • 4.3.2. Key growth factors and opportunities
    • 4.3.3. Market size and forecast
  • 4.1. Biochemistry research
    • 4.1.1. Key market trends
    • 4.1.2. Key growth factors and opportunities
    • 4.1.3. Market size and forecast

CHAPTER 5: WORLD RADIOPHARMACEUTICALS MARKET, BY MODALITY, 2014-2022

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. SPECT (Single-Photon Emission Computed Tomography)
    • 5.2.1. Market size and forecast
      • 5.2.1.1. Iodine 123
      • 5.2.1.2. Technetium 99m
      • 5.2.1.3. Xenon 133
      • 5.2.1.4. Thallium 201
      • 5.2.1.5. Fluorine 18
      • 5.2.1.6. Others
  • 5.3. PET (Positron Emission Tomography)
    • 5.3.1. Market size and forecast
      • 5.3.1.1. Rubidium 82
      • 5.3.1.2. Fluorine 18
      • 5.3.1.3. Others
  • 5.4. Beta-emitters
    • 5.4.1. Market size and forecast
      • 5.4.1.1. Phosphorus 32
      • 5.4.1.2. Iodine 131
      • 5.4.1.3. Strontium 89
      • 5.4.1.4. Yttrium 90
      • 5.4.1.5. Samarium 153
      • 5.4.1.6. Rhenium 186/188
      • 5.4.1.7. Others
  • 5.5. Alpha-emitters
    • 5.5.1. Market size and forecast
      • 5.5.1.1. Radium 223
      • 5.5.1.2. Bismuth 213
      • 5.5.1.3. Others
  • 5.6. Brachytherapy
    • 5.6.1. Market size and forecast
      • 5.6.1.1. Palladium 103
      • 5.6.1.2. Iodine 125
      • 5.6.1.3. Cesium 131
      • 5.6.1.4. Others

CHAPTER 6: WORLD RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2014-2022

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Oncology
    • 6.2.1. Market size and forecast
  • 6.3. Cardiology
    • 6.3.1. Market size and forecast
  • 6.4. Thyroid
    • 6.4.1. Market size and forecast
  • 6.5. Neurology
    • 6.5.1. Market size and forecast
  • 6.6. Others
    • 6.6.1. Market size and forecast

CHAPTER 7: WORLD RADIOPHARMACEUTICALS MARKET, BY END-USER, 2014-2022

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Hospitals and diagnostic centers
    • 7.2.1. Market size and forecast
  • 7.3. Research institutes
    • 7.3.1. Market size and forecast

CHAPTER 8: WORLD RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2014-2022

  • 8.1. Overview
    • 8.1.1. Market size and forecast
  • 8.2. North America
    • 8.2.1. Key market trends
    • 8.2.2. Key growth factors and opportunities
    • 8.2.3. Market size and forecast
      • 8.2.3.1. U.S. market size and forecast
      • 8.2.3.2. Canada market size and forecast
      • 8.2.3.3. Mexico market size and forecast
  • 8.3. Europe
    • 8.3.1. Key market trends
    • 8.3.2. Key growth factors and opportunities
    • 8.3.3. Market size and forecast
      • 8.3.3.1. Belarus market size and forecast
      • 8.3.3.2. Czech Republic market size and forecast
      • 8.3.3.3. Greece market size and forecast
      • 8.3.3.4. Hungary market size and forecast
      • 8.3.3.5. Rest of Europe market size and forecast
  • 8.4. Asia-Pacific
    • 8.4.1. Key market trends
    • 8.4.2. Key growth factors and opportunities
    • 8.4.3. Market size and forecast
      • 8.4.3.1. China market size and forecast
      • 8.4.3.2. India market size and forecast
      • 8.4.3.3. South Korea market size and forecast
      • 8.4.3.4. Pakistan market size and forecast
      • 8.4.3.5. Rest of Asia Pacific market size and forecast
  • 8.5. LAMEA
    • 8.5.1. Key market trends
    • 8.5.2. Key growth factors and opportunities
    • 8.5.3. Market size and forecast
      • 8.5.3.1. Brazil market size and forecast
      • 8.5.3.2. Argentina market size and forecast
      • 8.5.3.3. South Africa market size and forecast
      • 8.5.3.4. Rest of LAMEA market size and forecast

CHAPTER 9: COMPANY PROFILES

  • 9.1. Mallinckrodt plc.
    • 9.1.1. Company overview
    • 9.1.2. Company snapshot
    • 9.1.3. Operating business segments
    • 9.1.4. Business performance
    • 9.1.5. Key strategies and developments
    • 9.1.6. SWOT analysis
  • 9.2. General Electric Co.
    • 9.2.1. Company overview
    • 9.2.2. Company snapshot
    • 9.2.3. Operating business segments
    • 9.2.4. Business performance
    • 9.2.5. Key strategies and developments
    • 9.2.6. SWOT analysis
  • 9.3. Medtronic, plc. (Covidien, acquired by Medtronic)
    • 9.3.1. Company overview
    • 9.3.2. Company snapshot
    • 9.3.3. Operating business segments
    • 9.3.4. Business performance
    • 9.3.5. SWOT analysis
  • 9.4. Bayer AG
    • 9.4.1. Company overview
    • 9.4.2. Company snapshot
    • 9.4.3. Operating business segments
    • 9.4.4. Business performance
    • 9.4.5. Key strategies and developments
    • 9.4.6. SWOT analysis
  • 9.5. Cardinal Health, Inc.
    • 9.5.1. Company overview
    • 9.5.2. Company snapshot
    • 9.5.3. Business performance
    • 9.5.4. SWOT analysis
  • 9.6. Lantheus Medical Imaging, Inc.
    • 9.6.1. Company overview
    • 9.6.2. Company snapshot
    • 9.6.3. Business performance
    • 9.6.4. Key strategies and developments
    • 9.6.5. SWOT analysis
  • 9.7. IBA Group
    • 9.7.1. Company overview
    • 9.7.2. Company snapshot
    • 9.7.3. Operating business segments
    • 9.7.4. Business performance
    • 9.7.5. Key strategies and developments
    • 9.7.6. SWOT analysis
  • 9.8. Bracco Imaging S.p.A
    • 9.8.1. Company overview
    • 9.8.2. Company snapshot
    • 9.8.3. Operating business segments
    • 9.8.4. Business performance
    • 9.8.5. Key strategies and developments
    • 9.8.6. SWOT analysis
  • 9.9. NTP Radioisotopes SOC Ltd.
    • 9.9.1. Company overview
    • 9.9.2. Company snapshot
    • 9.9.3. Operating business segments
    • 9.9.4. Key strategies and developments
    • 9.9.5. SWOT analysis
  • 9.10. Advanced Accelerator Applications S.A.
    • 9.10.1. Company overview
    • 9.10.2. Company snapshot
    • 9.10.3. Operating business segments
    • 9.10.4. Key strategies and developments
    • 9.10.5. SWOT analysis

List of Tables

  • TABLE 1: CLINICAL TRIALS FOR RADIOPHARMACEUTICALS
  • TABLE 2: WORLD RADIOPHARMACEUTICALS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 3: WORLD RADIOPHARMACEUTICALS MARKET FOR DIAGNOSTICS, 2014-2022 ($MILLION)
  • TABLE 4: WORLD RADIOPHARMACEUTICALS MARKET FOR THERAPEUTICS, 2014-2022 ($MILLION)
  • TABLE 5: WORLD RADIOPHARMACEUTICALS MARKET FOR BIOCHEMISTRY RESEARCH, 2014-2022 ($MILLION)
  • TABLE 6: WORLD RADIOPHARMACEUTICALS MARKET, BY MODALITY, 2014-2022 ($MILLION)
  • TABLE 7: WORLD RADIOPHARMACEUTICALS MARKET FOR SPECT, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 8: WORLD RADIOPHARMACEUTICALS MARKET FOR PET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 9: WORLD BETA-EMITTERS RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 10: WORLD ALPHA-EMITTERS RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 11: WORLD BRACHYTHERAPY RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 12: WORLD RADIOPHARMACEUTICALS MARKET, BY NUMBER OF PROCEDURES, 2014-2022
  • TABLE 13: WORLD RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
  • TABLE 14: WORLD RADIOPHARMACEUTICALS MARKET FOR ONCOLOGY, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 15: WORLD RADIOPHARMACEUTICALS MARKET FOR CARDIOLOGY, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 16: WORLD RADIOPHARMACEUTICALS MARKET FOR THYROID, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 17: WORLD RADIOPHARMACEUTICALS MARKET FOR NEUROLOGY, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 18: WORLD RADIOPHARMACEUTICALS MARKET FOR OTHERS, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 19: WORLD RADIOPHARMACEUTICALS MARKET, BY END-USERS, 2014-2022 ($MILLION)
  • TABLE 20: WORLD RADIOPHARMACEUTICALS MARKET FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 21: WORLD RADIOPHARMACEUTICALS MARKET FOR RESEARCH INSTITUTES, BY GEOGRAPHY, 2014-2022 ($MILLION
  • TABLE 22: WORLD RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 23: NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 24: NORTH AMERICA RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 25: EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 26: EUROPE RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 27: ASIA PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 28: ASIA PACIFIC RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 29: LAMEA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 30: LAMEA RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 31: MALLINCKRODT PLC: COMPANY SNAPSHOT
  • TABLE 32: STRATASYS LTD: OPERATING SEGMENTS
  • TABLE 33: GENERAL ELECTRIC: COMPANY SNAPSHOT
  • TABLE 34: STRATASYS LTD.: OPERATING SEGMENTS
  • TABLE 35: MEDTRONIC INC.: COMPANY SNAPSHOT
  • TABLE 36: MEDTRONIC INC.: OPERATING SEGEMENTS
  • TABLE 37: BAYER : COMPANY SNAPSHOT
  • TABLE 38: BAYER: OPERATING SEGMENTS
  • TABLE 39: CARDINAL HEALTH, INC.: COMPANY SNAPSHOT
  • TABLE 40: LANTHEUS: COMPANY SNAPSHOT
  • TABLE 41: IBA GROUP: COMPANY SNAPSHOT
  • TABLE 42: IBA GROUP: OPERATING SEGMENTS
  • TABLE 43: BRACCO IMAGING: COMPANY SNAPSHOT
  • TABLE 44: BRACCO IMAGING: OPERATING SEGMENTS
  • TABLE 45: NTP RADIOISOTOPES: COMPANY SNAPSHOT
  • TABLE 46: NTP RADIOISOTOPES: OPERATING SEGMENTS
  • TABLE 47: ADVANCED ACCELERATOR: COMPANY SNAPSHOT
  • TABLE 48: NTP RADIOISOTOPES: OPERATING SEGMENTS

List of Figures

  • FIG. 1: TOP INVESTMENT POCKETS IN WORLD RADIOPHARMACEUTICALS MARKET
  • FIG. 2: TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2013 2016)
  • FIG. 3: PORTERS FIVE FORCE ANALYSIS
  • FIG. 4: TOP FACTORS IMPACTING WORLD RADIOPHARMACEUTICALS MARKET, 2014-2022
  • FIG. 5: PRESENT AND ESTIMATED NUMBER OF CANCER PATIENTS WORLDWIDE
  • FIG. 6: MOST COMMON CANCERS, MEN (INCIDENCE 2012)
  • FIG. 7: MOST COMMON CANCERS, WOMEN (INCIDENCE 2012)
  • FIG. 8: U.S. RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
  • FIG. 9: CANADA RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
  • FIG. 10: MEXICO RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
  • FIG. 11: BELARUS RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
  • FIG. 12: CZECH REPUBLIC RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
  • FIG. 13: GREECE RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
  • FIG. 14: HUNGARY RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
  • FIG. 15: REST OF EUROPE RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
  • FIG. 16: CHINA RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
  • FIG. 17: INDIA RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
  • FIG. 18: SOUTH KOREA RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
  • FIG. 19: PAKISTAN RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
  • FIG. 20: REST OF ASIA PACIFIC RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
  • FIG. 21: BRAZIL RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
  • FIG. 22: ARGENTINA RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
  • FIG. 23: SOUTH AFRICA RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
  • FIG. 24: REST OF LAMEA RADIOPHARMACEUTICALS MARKET, 2014-2022 ($MILLION)
  • FIG. 25: MALLINCKRODT PLC: REVENUE, 2013-2015 ($MILLION)
  • FIG. 26: MALLINCKRODT PLC: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
  • FIG. 27: MALLINCKRODT PLC: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 28: MALLINCKRODT PLC.: SWOT ANALYSIS
  • FIG. 29: GENERAL ELECTRIC: REVENUE, 2013-2015 ($MILLION)
  • FIG. 30: GENERAL ELECTRIC: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
  • FIG. 31: GENERAL ELECTRIC: REVENUE, BY GEOGRAPHY, 2015(%)
  • FIG. 32: GENERAL ELECTRIC: SWOT ANALYSIS
  • FIG. 33: MEDTRONIC: REVENUE, 2013-2015 ($MILLION)
  • FIG. 34: MEDTRONIC: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 35: MEDTRONIC: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
  • FIG. 36: MEDTRONIC: SWOT ANALYSIS
  • FIG. 37: BAYER: REVENUE, 2013-2015 ($MILLION)
  • FIG. 38: BAYER: REVENUE, BY SEGMENTS, 2015 (%)
  • FIG. 39: BAYER: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 40: BAYER: SWOT ANALYSIS
  • FIG. 41: CARDINAL HEALTH INC.: REVENUE, 2013-2015 ($MILLION)
  • FIG. 42: CARDINAL HEALTH INC.: REVENUE, BY SEGMENTS, 2015 (%)
  • FIG. 43: CARDINAL HEALTH INC: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 44: CARDINAL HEALTH, INC.: SWOT ANALYSIS
  • FIG. 45: LANTHEUS: REVENUE, 2013-2015 ($MILLION)
  • FIG. 46: LANTHEUS: SWOT ANALYSIS
  • FIG. 47: IBA GROUP: REVENUE, 2013-2015 ($MILLION)
  • FIG. 48: IBA GROUP: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
  • FIG. 49: IBA GROUP: SWOT ANALYSIS
  • FIG. 50: BRACCO IMAGING: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
  • FIG. 51: BRACCO IMAGING: REVENUE, BY GEOGRAPHY 2015 (%)
  • FIG. 52: BRACCO IMAGING: SWOT ANALYSIS
  • FIG. 53: NTP RADIOISOTOPES: SWOT ANALYSIS
  • FIG. 54: ADVANCED ACCELERATOR: SWOT ANALYSIS
Back to Top